The estimated Net Worth of William Fwfd Ventures Fund ... is at least $345 million dollars as of 28 February 2017. William Fund owns over 1,212,454 units of NovoCure Ltd stock worth over $345,014,416 and over the last 9 years William sold NVCR stock worth over $0.
William has made over 4 trades of the NovoCure Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently William exercised 1,212,454 units of NVCR stock worth $4,352,710 on 28 February 2017.
The largest trade William's ever made was exercising 1,212,454 units of NovoCure Ltd stock on 28 February 2017 worth over $4,352,710. On average, William trades about 459,088 units every 33 days since 2015. As of 28 February 2017 William still owns at least 20,024,052 units of NovoCure Ltd stock.
You can see the complete history of William Fund stock trades at the bottom of the page.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... et Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: